Tiziana Life Sciences Ltd. announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for intranasal foralumab to be studied in Alzheimer's disease. Foralumab could be a potentially groundbreaking treatment for Alzheimer's disease, given it targets the disease's underlying pathology by addressing the resulting neuroinflammation caused by the accumulation of toxic proteins in the brain.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.6227 USD | -2.70% | -16.42% | +11.20% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+11.20% | 62.46M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- TLSA Stock
- News Tiziana Life Sciences Ltd
- Tiziana Life Sciences Ltd. Announces FDA IND Clearance of Intranasal Foralumab for the Treatment of Alzheimer's Disease